OpenAI Acquires Orchestra Bio to Advance Life Sciences Rosalind Models and Tools
OpenAI announced the acquisition of Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. The two sides will continue development based on OpenAI's Rosalind models and tools for life sciences research, in order to streamline these processes and help new treatments reach patients sooner.
Why read this
AI score 60
OpenAI has acquired Orchestra Bio to advance Rosalind models and tools in the life sciences, giving readers insight into its positioning in this area.
Topics
View original postWe’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. Together, we’ll build on Rosalind, our AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients sooner. Welcome @ashokaraj_ and team! https://t.co/vi51OhznQn
View original
We’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. Together, we’ll build on Rosalind, our AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients sooner. Welcome @ashokaraj_ and team! https://t.co/vi51OhznQn
Body
OpenAI ❤️ Orchestra Bio
> OpenAI has acquired Orchestra Bio to work on Rosalind models and tools for life sciences research.
> "Orchestra Bio is a platform that helps biopharma teams coordinate the complex process of drug development."
AI advancements in life sciences are probably one of the most desired areas for many. So far, it seems like a top priority for Anthropic, OpenAI, and Google.